UBS Group’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

UBS Group’s Portfolio AST.WS Stock Details AST.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,870	Closed	-$2K	–	8430
2017 Q2	$2K	Buy	3,870 +2,615	+208%	+$1.18K	﹤0.01%	7466
2017 Q1	$0	Buy	1,255 +442	+54%	+$162	﹤0.01%	8474
2016 Q4	$0	Buy	813 +690	+561%	+$369	﹤0.01%	8496
2016 Q3	$0	Sell	123 -1,061	-90%	-$290	﹤0.01%	8398
2016 Q2	$0	Buy	+1,184	New	+$617	﹤0.01%	8420

UBS Group's AST.WS Position: Q3 2017 in Review

UBS Group sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2017, closing a stake of 3,870 shares — an estimated $2K sold.

UBS Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $2K in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

UBS Group reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2017 after selling out during the quarter.
UBS Group sold 3,870 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2017, an estimated $2K.
UBS Group first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 5 quarters.
UBS Group's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $2K in Q2 2017.
3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.